<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; between</title>
	<atom:link href="http://www.tapanray.in/tag/between/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>&#8216;Big Pharma&#8217; Prowls Falter: Triggers Off Yet Another Critical Debate</title>
		<link>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-prowls-falter-triggers-off-yet-another-critical-debate</link>
		<comments>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/#comments</comments>
		<pubDate>Mon, 25 Nov 2013 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[council. India]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pitroda]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sam]]></category>
		<category><![CDATA[SME]]></category>
		<category><![CDATA[sparks]]></category>
		<category><![CDATA[stricter]]></category>
		<category><![CDATA[stumbles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[triggers]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Wharton]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3101</guid>
		<description><![CDATA[The &#8216;Big Pharma&#8217; prowls faltered yet again exposing the ‘fault line’ to all, when the GSK global head honcho, a pharma icon in his own right, Sir Andrew Witty supported the pharmaceutical policy of India, while in the country earlier &#8230; <a href="http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Intervened…But ‘Price Control’ needs striking a right balance between ‘Affordability’ and ‘Availability’ of medicines for Patients’ Sake</title>
		<link>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients</link>
		<comments>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/#comments</comments>
		<pubDate>Mon, 08 Oct 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intervened]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines for Patients’ Sake]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1084</guid>
		<description><![CDATA[On October 3, 2012, the Supreme Court bench of Justice GS Singhvi and Justice SJ Mukhopadhayareportedly asked the government not to disturb the existing price control mechanism while including all medicines featuring  in the National List of Essential Medicines 2011 (NLEM &#8230; <a href="http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma industry requires striking a right balance between ethical obligations to shareholders and ethical obligations to patients</title>
		<link>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients</link>
		<comments>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[obligations]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[requires]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=6</guid>
		<description><![CDATA[On September 15, 2012, while delivering his keynote address in a pharmaceutical industry function, Dr. Sam Pitroda, the Chicago based Indian, creator of the telecom revolution in India and the Advisor to the Prime Minister on Public Information, Infrastructure &#38; &#8230; <a href="http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-industry-requires-striking-a-right-balance-between-ethical-obligations-to-shareholders-and-ethical-obligations-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For greater transparency in the relationship between physicians and the pharmaceutical companies, does India need an Act like, proposed ‘The Physician Payment Sunshine Act’ of the USA?</title>
		<link>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa</link>
		<comments>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/#comments</comments>
		<pubDate>Mon, 16 Nov 2009 01:30:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[proposed]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=724</guid>
		<description><![CDATA[As we discussed earlier, to make the pharmaceutical companies disclose and report various types of payments made to the physicians, two Senators of the United States of America, Chuck Grassley and Herb Kohl introduced a bill called ‘The Physician Payment &#8230; <a href="http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare services in India &#8230; growing disparity between urban and rural population – can ‘Telemedicine’ play a significant role?</title>
		<link>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role</link>
		<comments>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/#comments</comments>
		<pubDate>Sun, 05 Apr 2009 06:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[disparity]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[e-healthcare]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[play]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=923</guid>
		<description><![CDATA[Healthcare Industry in India is currently valued at US$ 35 billion. This industry is expected to record a turnover of US$ 75 billion in 2012 and US$ 150 billion in 2017, reports Technopak Advisors in their report titled “India Healthcare &#8230; <a href="http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
